Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease-Reference-Cited by-同舟云学术

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Published:2015-01 Issue:1 Volume:10 Page:156-163
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Hoffknecht Petra,Tufman Amanda,Wehler Thomas,Pelzer Theo,Wiewrodt Rainer,Schütz Martin,Serke Monika,Stöhlmacher-Williams Jan,Märten Angela,Maria Huber Rudolf,Dickgreber Nicolas J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference49 articles.

1. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

2. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

3. Targeting EGFR in non-small-cell lung cancer;Doroshow;N Engl J Med,2005

4. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer;Johnson;Cancer Res,2005

5. Defining clinically relevant molecular subsets of lung cancer;Pao;Cancer Chemother Pharmacol,2006

Cited by 231 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

2. Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A;JCO Precision Oncology;2024-07

3. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I;Critical Reviews in Oncology/Hematology;2024-07

4. Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis;Heliyon;2024-05

5. Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases;Frontiers in Oncology;2024-01-10